DEVELOPMENT OF DRUG DELIVERY SYSTEMS:BIOSYNTHETIC HYBRID

药物输送系统的开发：生物合成混合药物

• 批准号: 6401391
• 负责人: IAN J MCLENNAN
• 金额: $ 13.98万
• 依托单位: ECOSYNTHETIX, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-07 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6401391
• 关键词: athymic mouse; biodegradable product; biomaterial development /preparation; camptothecin; carmustine; chemical structure; drug adverse effect; drug delivery systems; drug design /synthesis /production; drug screening /evaluation; drug vehicle; human tissue; microcapsule; nanotechnology; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; pharmacokinetics

DESCRIPTION (provided by applicant): The development of new treatment modalities for neoplastic diseases has coincided with the invention of in vivo drug delivery systems. The in vivo drug delivery systems can, in principal, ameliorate the harmful side effect of antineoplastic agents. Over the past 4 years, ECOSYNTHETIX has developed a series of biobased products including new sugar based vinyl macromers that serve as building blocks for a variety of polymer technologies. These sugar macromers have unusual properties that have been exploited in the area of water-based copolymers used in applications such as environmentally friendly pressure sensitive adhesives and water-based inks. ECOSYNTHETIX has optimized the process for incorporation of the sugar macromers into various copolymers and novel cross-linked starch nanoparticles. As part of this proposal, a process is proposed for production of novel macromer/starch hybrid materials that are inherently non-toxic. The hybrid materials will be developed for drug delivery systems to be used in the treatment of cancer. The hybrid nanospheres will be used to encapsulate several different antineoplastic agents including camptothecin derivatives and BCNU. The starch hybrids will be cast as thin films with the incorporated drug. The release profiles of the thin films will be determined. The physical properties of the drug-nanosphere complex will be studied. In addition, the release profiles of the drug-nanosphere complexes will be determined under physiological conditions. PROPOSED COMMERCIAL APPLICATIONS: Starch nanosphere hybrid particles represent a new class of particles to be used as drug delivery systems for treatment of manner. These nanosphere particles could potentially extend the use of antitumor agents such as namtothecin derivatives, BCNU.

描述（由申请人提供）： 开发有关肿瘤疾病的新治疗方式 与体内药物输送系统的发明相吻合。 体内 药物输送系统可以改善 抗肿瘤剂。 在过去的四年中，Ecosynthetix开发了 一系列生物基产品，包括新的基于糖的乙烯基宏观分子 充当各种聚合物技术的基础。 这些糖 MacRomers具有在该区域中被利用的异常特性 水性共聚物用于环境友好的应用 压力敏感的粘合剂和水基油墨。 Ecosynthetix已优化 将糖宏掺入各种共聚物中的过程 和新型的交联淀粉纳米颗粒。 作为本提案的一部分， 提出了用于生产新型宏观/淀粉混合材料的过程 本质上是无毒的。 将开发用于的混合材料 用于治疗癌症的药物输送系统。 杂种 纳米球将用于封装几种不同的抗肿瘤 包括Camptothecin衍生物和BCNU在内的代理。 淀粉混合动力车将 用掺入药物作为薄膜铸造。 释放配置文件 将确定薄膜。 药物 - 纳米球的物理特性 复杂将研究。 另外，释放曲线 在生理条件下，将确定药物 - 纳米复合物。 拟议的商业应用： 淀粉纳米层杂交颗粒代表了一类新的颗粒，用于用于治疗方式的药物输送系统。这些纳米球颗粒可能有可能扩展使用抗肿瘤剂，例如Namtothecin衍生物BCNU。